Tests oral LW402 tablets for moderate-to-severe atopic dermatitis
Tests oral LW402 tablets against placebo in adults with moderate-to-severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with moderate-to-severe atopic dermatitis (eczema) to test LW402 tablets against placebo.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Moderate-to-severe atopic dermatitis, with a history of at least 1 year. Lesions cover at least 10% of body surface area, IGA score at least 3, and EASI score at least 16.
Main reasons for not taking part
- Past allergic reaction to Janus kinase (JAK) inhibitors
- Current or past autoimmune disease other than atopic dermatitis, such as lupus or inflammatory bowel disease
- Other skin conditions that may interfere with assessing atopic dermatitis, such as contact dermatitis or psoriasis
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07370909, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Jianzhong ZhangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
- Trial code
- NCT07370909
- Record updated
- 27 August 2026
- Original description
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.Read full original descriptionShow less
A Multi-center, Randomized, Double Blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Moderate-to-severe Atopic Dermatitis.
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
Inclusion: Subjects voluntarily provided informed consent and agreed to participate in the study; Gender: no restrictions; Age: 18 to 75 years inclusive (as of the date of signing the informed consent form); At screening, subjects met the Hanifin-Rajka diagnostic criteria for atopic dermatitis (AD) (Appendix 4) and had a documented AD history of ≥1 year prior to screening; At screening and baseline visits, subjects were required to have moderate-to-severe atopic dermatitis (AD) with all three of the following criteria satisfied:; Total AD lesion area ≥ 10% of body surface area (BSA); Investigator's Global Assessment (IGA) score ≥ 3; Eczema Area and Severity Index (EASI) score ≥ 16.
Exclusion: Subjects with a documented history of hypersensitivity to Janus kinase (JAK) inhibitors; Subjects with current or a history of autoimmune diseases other than atopic dermatitis (AD) (e.g., systemic lupus erythematosus [SLE], inflammatory bowel disease [IBD], Felty's syndrome, scleroderma, inflammatory myopathy, other connective tissue diseases, overlap syndrome) or other skin conditions that may interfere with AD assessment (e.g., contact dermatitis, psoriasis).